Monterey Bio Acquisition Corp. (MTRY) Sells Sponsor Shares and Rebrands
by Marlena Haddad on 2023-03-10 at 10:31am

Monterey Bio Acquisition Corp. (NASDAQ:MTRY) announced in an 8-K this morning that its co-sponsors, NorthStar Bio Ventures and Chardan Monterey Investments, entered into a share transfer agreement and will rebrand the company.

As part of the agreement, NorthStar transferred 478,125 shares of MTRY to Chardan for a purchase price of $0.006 per share, which is equal to the initial purchase price it paid for its founder shares.

The co-sponsors then entered into agreements with three new directors of Monterey Bio to transfer an aggregate of 35,000 founder shares to each director. Each of the newly appointed officers and directors has agreed to vote all of their shares of common stock, including any founder shares, in favor of a business combination, and waived certain conversion rights with respect to their founder shares.

As a result, Monterey Bio will undergo a change in management. Sanjeev Satyal tendered his resignation as CEO and will be replaced by Murat Omur, who brings 15 years of investment banking experience in the healthcare M&A space. Mr. Omur serves as Managing Director of Healthcare Investment Banking and Principal Investments at Chardan Capital Markets. Prior to joining Chardan, Mr. Omur was an Executive Director in Healthcare Investment Banking at Nomura Securities.

Additionally, William McKeever stepped down as CFO and director and is to be replaced by Sean McGann, who also brings over 15 years of investment banking and strategy experience. Mr. McGann is a Managing Director in the Principal Investments Group for Chardan Capital Markets, a position he has held since 2020. Previously, Mr. McGann was at Citigroup where he was the Director of Product Strategy for the Corporate and Investment Bank and served as an Investment Banker covering clients in the Financial Technology and Asset Management sectors.

Chris Coleman, Jory Des Jardins and Roderick Hardamon, were appointed as directors. Mr. Hardamon and Mr. Coleman were appointed to the audit committee of the company, and Mr. Hardamon was also designated as the “audit committee financial expert.” Jonas Grossman was appointed as Executive Chairman.

The SPAC announced the pricing of its $100 million IPO in September 2021 but has not yet found a target to combine with. It intends to partner with a biotech company, specifically within the oncology or immunology sector, that has demonstrated success and is primed to thrive in the rapidly evolving biotech industry.

By implementing these new key additions to the board of directors and management team, Monterey hopes to expand its acquisition strategy to include a broader universe of disruptive technology targets.

Recent Posts
by Nicholas Alan Clayton on 2024-06-12 at 10:12am

Perceptive Capital Solutions Corp announced the pricing of its $75 million IPO and its shares are expected to begin trading on the Nasdaq under the symbol “PCSC”, Wednesday, June 12, 2024. The new SPAC intends to focus its target search on the North American and European life sciences and medical technology sectors where its management...

by Nicholas Alan Clayton on 2024-06-12 at 8:23am

At the SPAC of Dawn The ARYA team has been among the SPAC market’s most steady dealmakers and they dropped a new presentation this morning for ARYA Sciences IV‘s (NASDAQ:ARYD) pending combination with medical device manufacturer Adagio Medical. Much of the deck rehashes already released information, but it has given more texture on how the...

by Nicholas Alan Clayton on 2024-06-11 at 12:22pm

EQV Ventures (NYSE:EQV.U) is the largest SPAC to file since April 2023 as it seeks a $350 million IPO that reflects the ongoing experimentation in underwriting approaches over the last two months of 2024. It is BTIG’s first new SPAC filed for 2024, and it is structured to compensate the firm in a unique way....

by Nicholas Alan Clayton on 2024-06-11 at 8:14am

At the SPAC of Dawn As both SPAC and traditional-way IPO activity picks back up in 2024, SPAC teams might want to brush up on their Spanish as they compete for targets. Spain has not traditionally been considered a tech innovation hotbed, but the combined enterprise value of Spanish startups hit €100 billion last year,...

by Nicholas Alan Clayton on 2024-06-10 at 8:08pm

Centurion Acquisition Corp announced the pricing of its $250 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “ALFUU”, Tuesday, June 11, 2024. The new SPAC aims to combine with a technology company with a focus on video gaming, interactive entertainment and enabling services and technologies, cybersecurity, artificial...


Copyright © 2023 SPACInsider, Inc. All Rights Reserved